Using a panel of 25 HIV isolates from multiple clades (Supplementary Table 1), we confirmed the ability of Leronlimab to mimic the resistance conferred by the CCR5Δ32/Δ32 phenotype onto CD4+ T cells from CCR5 wild-type donors, thereby protecting these cells from infection with CCR5-tropic isolates from multiple geographical origins (Fig. 1b). The gene discussed is CCR5; the disease is infection.